US FDA Shelves Fast-Track Priority Voucher Pilot Program
The US Food and Drug Administration (FDA) has decided to discontinue its fast-track drug review priority voucher pilot program. The initiative, which was launched in June 2025 under the direction of former Commissioner Marty Makary during the Trump administration, aimed to accelerate certain drug approval processes through a voucher system. The decision follows internal reviews and reports from sources familiar with the matter. By shelving this program, the FDA is shifting away from the specific incentive structure intended to expedite pharmaceutical development timelines established by the previous administration's leadership.
Topics: drug review initiative FDA regulatory policy change
Read the full article at Seeking Alpha
Part of the story US FDA shelves fast-track priority voucher pilot program: Reuters (2 articles)